Institute for Clinical & Economic Review Publishes Final Report and Policy Recommendations for Hemophilia a Therapies
November 21, 2020
November 21, 2020
BOSTON, Massachusetts, Nov. 21 (TNSRes) -- The Institute for Clinical and Economic Review issued the following announcement on Nov. 20:
The Institute for Clinical and Economic Review (ICER) today released an Final Evidence Report and Report-at-a-Glance assessing the comparative clinical effectiveness and value of valoctocogene roxaparvovec (Roctavian(TM), BioMarin Pharmaceutical) and emicizumab (Hemlibra(R), Genentech) for the treatment of hemophilia A. In August 2020, BioMarin rece . . .
The Institute for Clinical and Economic Review (ICER) today released an Final Evidence Report and Report-at-a-Glance assessing the comparative clinical effectiveness and value of valoctocogene roxaparvovec (Roctavian(TM), BioMarin Pharmaceutical) and emicizumab (Hemlibra(R), Genentech) for the treatment of hemophilia A. In August 2020, BioMarin rece . . .